Loading
A phase 2 trial of Infigratinib and Capmatinib in Melanoma, run by Pfizer, completed.
LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma is a phase 2 interventional study registered as NCT02159066 by Pfizer, with 158 participants recorded, started 2014-07-23 and reaching its primary completion in 2023-01-10. Interventions recorded: LGX818, MEK162, LEE011, BGJ398, BKM120, INC280. Conditions recorded: Melanoma.
Linked to the drug Infigratinib because the registry names it among its interventions and Melanoma among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
158 enrolled.
95% CI 0.1 to 13.8; Figures from the ClinicalTrials.gov results section (first posted 2024-03-05), not from a publication · 95% CI NA to NA · 95% CI 0.0 to 24.7 · 95% CI 0.0 to 45.9
Source95% CI 6.0 to 16.7; Figures from the ClinicalTrials.gov results section (first posted 2024-03-05), not from a publication · 95% CI NA to NA · 95% CI 1.7 to NA · 95% CI 0.4 to NA
Source95% CI 8.1 to 15.0; Figures from the ClinicalTrials.gov results section (first posted 2024-03-05), not from a publication · 95% CI 2.1 to 4.7
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall Response Rate (ORR): Part IIprimary | Part II: Encorafenib + Binimetinib + Ribociclib | 38 | 2.6% | - | - | link |
| Part II: Encorafenib + Binimetinib + Infigratinib | 1 | 0% | ||||
| Part II: Encorafenib + Binimetinib + Capmatinib | 13 | 0% | ||||
| Part II: Encorafenib + Binimetinib + Buparlisib | 6 | 0% | ||||
| Overall Survival (OS): Part II | Part II: Encorafenib + Binimetinib + Ribociclib | 38 | 10.4 months | - | - | link |
| Part II: Encorafenib + Binimetinib + Infigratinib | 1 | 20.8 months | ||||
| Part II: Encorafenib + Binimetinib + Capmatinib | 13 | 5.6 months | ||||
| Part II: Encorafenib + Binimetinib + Buparlisib | 6 | 2.5 months | ||||
| Progression-Free Survival (PFS): Part I | Part I: Encorafenib + Binimetinib (Naive) | 75 | 11.1 months | - | - | link |
| Part I: Encorafenib + Binimetinib (Non-naive) | 83 | 3.3 months |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Infigratinib and the tag pipeline.
Shares Infigratinib and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/